Bulletin
Investor Alert

Topics

Health and Human Services Department

10:01 a.m. Dec. 28, 2020 - By Ciara Linnane
U.S. has had more than 19 million COVID-19 cases, and Fauci is getting worried about a post-holiday surge Relief as Trump signs relief bill and Novavax is starting a Phase 3 trial of its vaccine candidate in the U.S. and MexicoThe global tally for confirmed cases of the coronavirus-borne illness COVID-19 topped 81 million on Monday, while the U.S. case tally topped 19 million, and experts warned the next few weeks will be hard after many Americans traveled over the Christmas holiday.
10:22 a.m. Dec. 10, 2020 - By Ciara Linnane
U.S. sets record one-day death toll from coronavirus as FDA committee meets to review Pfizer–BioNTech vaccine FDA head says initial assessment is ‘this is a vaccine that does meet our criteria. ... But we do want to hear from the vaccine advisory committee.’The U.S. set fresh records for single-day fatalities from the coronavirus illness COVID-19 and hospitalizations, as a U.S. regulatory advisory committee gathered to offer its verdict on the vaccine developed by Pfizer Inc. and its German partner BioNTech SE.
10:26 a.m. Dec. 9, 2020 - By Ciara Linnane
U.S. coronavirus case tally climbs to 15 million from 14 million in just five days U.S. sets fresh record for COVID-19 hospitalizations; Angela Merkel pleads with Germans to limit gatherings during holidaysThe global case tally for the coronavirus illness COVID-19 climbed above 68 million on Wednesday and the U.S. tally rose above 15 million as the virus continued to race across the nation, filling hospitals with record numbers of patients
2:18 a.m. Dec. 7, 2020 - By Quentin Fottrell
Joe Biden’s pandemic plan: Restore Obamacare, mandatory masks, paid sick leave and free COVID-19 tests The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face’The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face.’
2:41 a.m. Nov. 17, 2020 - By Ciara Linnane
Moderna’s COVID-19 vaccine candidate sparks market rally after achieving 94.5% efficacy in late-stage trial and requires only standard refrigeration Biotech says vaccine remains stable at refrigerated temperatures for longer times, so distribution could be a lesser challengeModerna Inc. said Monday its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy, a far higher benchmark than originally expected, sparking a broad-based market rally.
9:47 a.m. Nov. 9, 2020 - By Quentin Fottrell
Joe Biden announces his COVID-19 task force The team of public-health experts will advise the Biden administration and the transition’s COVID-19 staffThe team of public-health experts will advise the Biden administration and the transition’s COVID-19 staff.
2:42 a.m. Nov. 9, 2020 - By Jaimy Lee
To defeat COVID-19, ‘we need a unified national strategy,’ says public health expert Dr. Howard Koh Koh served as assistant secretary of health during the H1N1 flu pandemic in 2009Dr. Howard Koh knows what it’s like to be a government official running a pandemic response.
4:38 a.m. Oct. 14, 2020 - By Jaimy Lee
There are seven coronavirus vaccine candidates being tested in the U.S. — here’s where they stand At least four of the still investigational vaccines have moved into Phase 3 clinical trialsThe race to develop a safe and effective COVID-19 vaccine is well under way, setting the stage to bring to market the fastest vaccine in history.
11:29 a.m. Sept. 18, 2020 - By Ciara Linnane
Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists HHS revised the guidelines to say asymptomatic patients don’t need testing and then ‘dropped’ them on CDC site without vetting, New York Times reportsThe number of confirmed cases of the coronavirus that causes COVID-19 rose above 30 million on Friday, and the death toll rose above 946,000, with the U.S. death toll edging closer to 200,000, or almost a fifth of the global tally.
4:40 p.m. Sept. 13, 2020 - By Andrew Restuccia
Trump signs executive order aimed at lowering prescription drug prices Drug companies criticize order, which has little immediate effectPresident Donald Trump signed an executive order on Sunday to reduce the cost of prescription drugs for U.S. seniors by more closely aligning prices with what pharmaceutical companies charge in other countries.
8:12 a.m. Aug. 31, 2020 - By Barbara Kollmeyer
European stocks fall on the last day of August trading Suez surges on deal news, Philips drops on warning European stocks struggled on Monday, in a month that’s set to deliver a 3.3% gain for the region’s main index.
8:02 a.m. Aug. 18, 2020 - By Jaimy Lee
Teva's stock sinks 10% on False Claims allegationsShares of Teva Pharmaceutical Industries Ltd. tumbled 10.9% in trading on Tuesday after the U.S. government alleged that the drugmaker had illegally paid Medicare co-pays for the multiple sclerosis drug Copaxone through two foundations. The Department of Justice said doing so violates anti-kickback laws. Copaxone has long been Teva's top-selling drug, though sales have dwindled in recent years. The drug generated $4.2 billion in sales in 2014; however, in the first six months of 2020, it brought in $628 million in the U.S. and Europe combined. The government alleges that Teva gave funding to The Assistance Fund and the Chronic Disease Fund to cover Medicare co-pays for Copaxone between 2007 and 2015. "Drug manufacturers that offer kickbacks in order to boost profits - as alleged in this case - drive up health care costs for everyone and undermine the public's trust in the health care system," Phillip Coyne, an official for the U.S. Department of Health and Human Services' Office of Inspector General, said in a news release. Anti-kickback laws do not allow drugmakers to provide financial incentives, such as covering the cost of a drug's co-pay, to entice Medicare beneficiaries to select that medication. "This case brought by the Department of Justice regarding these charitable contributions only seeks to further restrict patients' access to important medicines and health care," a Teva spokesperson said in an email. "The company will vigorously defend itself against these allegations." Teva's stock is up 14.1% for the year, while the S&P 500 has gained 4.7%.
2:39 a.m. Aug. 13, 2020 - By Ciara Linnane
Moderna stock rally fades as analysts weigh in on what U.S. government supply deal means for COVID-19 vaccine pricing ‘We now await visibility on what agreements with other countries might look like but see the news as a positive signal re: Moderna’s potential entry into a commercial space often dominated by big-cap,’ says one analystThe rally in Moderna Inc. shares sparked by news late Tuesday that the U.S. government has ordered 100 million doses of its COVID-19 vaccine candidate dissipated on Wednesday, as analysts weighed in on what the order means for pricing.
12:58 a.m. Aug. 10, 2020 - By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
9:56 a.m. Aug. 5, 2020 - By Ciara Linnane
Coronavirus update: Global death toll tops 700,000 with 18.5 million confirmed cases and U.S. accounts for more than a quarter Disney posts an almost $5 billion loss as parks, film and cruise business hammered by pandemic, leaving only streaming to shineThe number of confirmed deaths across the globe from the coronavirus illness COVID-19 climbed above 700,000 on Wednesday, according to data aggregated by Johns Hopkins University, as the case tally climbed above 18.5 million, with the U.S. accounting for 4.77 million of that total, or more than a quarter.
5:37 a.m. July 19, 2020 - By Quentin Fottrell
White House animus toward Fauci may escalate as he calls coronavirus pandemic ‘your worst nightmare, the perfect storm’ ‘This was avoidable,’ says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, continues run of media appearances that are likely to only further upset the administrationAnthony Fauci, director of the National Institute of Allergy and Infectious Diseases, continues with media appearances that are likely to only further upset the administration.
7:16 a.m. July 18, 2020 - By Jaimy Lee
Rule change for how hospitals report coronavirus data to government comes under fire ‘This decision raises more questions than answers,’ said one policy expertA federal dashboard that provides information to the public about COVID-19 data that is provided by hospitals has not been updated since a rapidly implemented rule for how hospitals report that kind of data was put into place.
5:43 a.m. July 14, 2020 - By Quentin Fottrell
As COVID-19 cases surge in the U.S., Trump administration turns ire on Democrats, media — and Anthony Fauci Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he has not briefed the president since June 2Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he has not briefed the president since June 2.
5:25 a.m. July 4, 2020 - By Jaimy Lee
After months of speculation, investors get excited about Pfizer, BioNTech’s coronavirus vaccine candidate FDA’s new guidelines for vaccine development ‘do not suggest that a widely usable vaccine will be available at ‘warp speed’ in 2020,’ says one analystThe path to a COVID-19 vaccine has started to come into view this week, following the stock-moving disclosures of preliminary clinical data for two candidates and a rigorous new regulatory road map from the Food and Drug Administration.
2:38 p.m. July 1, 2020 - Associated Press
Global health experts criticize U.S. deal to hog supply of coronavirus drug U.S. makes deal with Gilead for 90% of remdesivir for next 3 monthsPublic health experts on Wednesday criticized the U.S. for securing a large supply of the only drug licensed so far to treat COVID-19.
5:50 a.m. July 1, 2020 - By Jaimy Lee
UPDATE: U.S. government to secure majority of Gilead's remdesivir supply through SeptemberHealth officials said Monday that the U.S. government will receive 500,000 treatment courses of Gilead Sciences Inc.'s remdesivir through September that can then be purchased by American hospitals. This means that the U.S. will receive 100% of Gilead's total remdesivir production in July and 90% in August and September, in Europe and the U.K. Gilead in May received an emergency use authorization from the Food and Drug Administration for remdesivir as a treatment for some severely ill, hospitalized COVID-19 patients. Gilead earlier on Monday; the drug will cost $2,340 for a 5-day course of treatment in developed countries, with one exception. The cost of treatment for people who have commercial health insurance is $3,120. The Department of Health and Human Services said in a news release that AmerisourceBergen Corp. will continue to ship the drug. Following the EUA in early May, Gilead had donated more than 100,000 doses of remdesivir to the U.S. government, which then dispensed the drug to hospitals.
8:03 a.m. June 6, 2020 - By Jeff Reeves
Buy this, not that — 5 stocks to trade into now and 5 to avoid These stocks for your buy list have strong momentum and solid potentialThese stocks for your buy list have strong momentum and solid potential.
Browse topics:

Filter results by

Industry

Health-care (78)

Pharmaceuticals (24)

Media (23)

Medical Products (22)

Biotechnology (18)

Software (16)

Location

Us (118)

Asia Pacific (24)

China (24)

Europe (21)

Eu (19)

Latin America (5)

Link to MarketWatch's Slice.